Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease

Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease

Background: Recombinant human erythropoietin (rHuEPO) is an effective treatment for renal anemia. Recently, there is evidence to suggest that rHuEPO may reduce podocyte injury in diabetic kidney disease (DKD). However, there is no published study on the change in podocyte injury marker levels before...

Full description

Bibliographic Details
Main Authors: Lingfeng Zeng, Jack Kit-Chung Ng, Winston Wing-Shing Fung, Gordon Chun-Kau Chan, Kai-Ming Chow, Cheuk-Chun Szeto
Format: Article
Language:English
Published: KeAi Communications Co. Ltd. 2023-01-01
Series:Advances in Biomarker Sciences and Technology
Subjects:
Podocyte
Proteinuria
Chronic kidney disease
Anemia
Online Access:http://www.sciencedirect.com/science/article/pii/S2543106423000066

Similar Items

Similar Items